GlassScriptPhysician profile
Colleen L Keating
NPI 1295701373
$3,480.65
in general payments reported to CMS, 2019-2025
34 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $432 · 2021: $655 · 2022: $270 · 2023: $328 · 2024: $477 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $506.27 | 2019-2025 | |
| Abbvie INC. | $421.35 | 2020-2025 | |
| Amgen INC. | $352.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $290.09 | 2019-2024 | Breztri, Airsupra |
| Novo Nordisk INC | $205.70 | 2019-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $191.99 | 2019-2020 | |
| Lilly USA, LLC | $187.44 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Mayne Pharma Commercial LLC | $171.12 | 2021 | |
| Glaxosmithkline, LLC. | $134.24 | 2019-2025 | Bexsero, Pediarix, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.23 | 2019-2023 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $80.82 | 2021-2025 | Livalo, Zoryve |
| Teva Pharmaceuticals USA, INC. | $79.71 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.81 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $68.65 | 2024-2025 | Voquezna |
| Bausch Health US, LLC | $67.18 | 2021-2023 | Wellbutrin, Aplenzin |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $57.00 | 2019-2025 | M-M-R II, Gardasil 9, Capvaxive |
| Dynavax Technologies Corporation | $55.50 | 2019-2025 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $54.49 | 2020-2021 | |
| Sanofi Pasteur INC. | $46.04 | 2020-2023 | |
| Shire North American Group INC | $37.37 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.56 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $28.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.57 | 2019-2020 | |
| Axsome Therapeutics, INC. | $17.85 | 2025 | Auvelity |
| Genentech USA, INC. | $17.56 | 2019 | |
| Astellas Pharma US INC | $15.98 | 2019 | |
| Therapeuticsmd, INC. | $14.58 | 2019 | |
| Mylan Specialty L.P. | $14.57 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.38 | 2021 | |
| Exact Sciences Corporation | $13.81 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $13.53 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.33 | 2020 | |
| Amarin Pharma, INC. | $12.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Keating listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.